Avanos Medical Still Anticipates FY24 Revenue From Cont. Ops Of $685M - $705M (Est $695.40M), Adjusted EPS From Cont. Ops Of Between $1.30 - $1.45 (Est $1.38)
Portfolio Pulse from Benzinga Newsdesk
Avanos Medical has reaffirmed its FY24 revenue guidance from continuing operations to be between $685M and $705M, with an estimated $695.40M. The company also expects adjusted EPS from continuing operations to be between $1.30 and $1.45, with an estimated $1.38.
July 31, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avanos Medical has reaffirmed its FY24 revenue and adjusted EPS guidance, aligning closely with market estimates. This stability in guidance is likely to maintain investor confidence.
The reaffirmation of revenue and EPS guidance within the expected range suggests stability and predictability in Avanos Medical's financial performance. This is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100